Table 1 Baseline characteristics
Variable | Prior revascularization N = 497 (%) | No revascularization N = 109 (%) | P value |
|---|---|---|---|
Age | 66.3 ± 10.2 | 66.4 ± 9.9 | 0.90 |
Women | 61 (12.3) | 11 (10.1) | 0.62 |
Ejection fraction | 31.0 ± 12.2 | 28.4 ± 11.2 | 0.04 |
Primary Prevention | 292 (58.8) | 65 (59.6) | 0.91 |
Cardiac resynchronization therapy | 95 (19.1) | 19 (17.4) | 0.82 |
Heart Failure | 338 (68.0) | 82 (75.2) | 0.17 |
Atrial fibrillation | 166 (33.4) | 38 (34.9) | 0.82 |
Chronic obstructive pulmonary disease | 82 (16.5) | 14 (12.8) | 0.39 |
Diabetes | 191 (38.4) | 34 (31.2) | 0.19 |
Hypertension | 322 (64.8) | 63 (57.8) | 0.19 |
Hyperlipidemia | 339 (68.2) | 63 (57.8) | 0.044 |
Peripheral vascular disease | 77 (15.5) | 16 (14.7) | 0.88 |
Creatinine (umol/L) | 104.8 ± 61.6 | 103.2 ± 60.3 | 0.81 |
NYHA Class III | 128/489 (26.2) | 32/105 (30.4) | 0.29 |
NYHA IV | 6/489 (1.2) | 3/105 (2.9) | 0.95 |
Charlson Comorbidity Index | 5.7 (1.7) | 5.6 (1.8) | 0.45 |
Beta Blocker | 460 (92.6) | 104 (95.4) | 0.40 |
Angiotensin converting enzyme inhibitor/angiotensin receptor blocker | 426 (85.7) | 93 (85.3) | 0.88 |
Spironolactone | 98 (19.7) | 24 (22.0) | 0.60 |
Loop Diuretic | 270 (54.3) | 60 (55.1) | 0.92 |
Oral anticoagulant | 159 (32.0) | 41 (37.6) | 0.26 |
Digoxin | 86 (17.3) | 24 (22.0) | 0.27 |
Amiodarone | 88 (17.7) | 21 (19.3) | 0.68 |
Other antiarrhythmic | 16 (3.2) | 5 (4.6) | 0.56 |